cancer pain
Pain · 2006–2015
5decisions
1medicine
0carried consumer input
0individual submissions
No submission for this condition has carried consumer input, including the one made since the comments facility came into use.
Every decision
| Medicine | Meeting | Outcome | Consumer input |
|---|---|---|---|
| fentanyl citrate Breakthrough pain in patients undergoing palliative care for cancer who are receiving maintenance opioid therapy and are unable to tolerate further escalation… | Nov 2015 | Recommended with restriction | none received |
| fentanyl citrate Treatment of breakthrough pain in patients with cancer who are receiving opioids for persistent pain and where further escalation in the dose of morphine for… | Mar 2013 | Not recommended | no section in document |
| fentanyl citrate treatment of breakthrough pain in palliative care patients who are receiving opioids for their underlying persistent cancer pain where morphine is… | Nov 2007 | Recommended with restriction | no section in document |
| Fentanyl citrate Management of breakthrough cancer pain in palliative care patients who are receiving opioids for their underlying persistent cancer pain where morphine is… | Mar 2006 | Recommended | no section in document |
| fentanyl citrate Management of breakthrough cancer pain in palliative care patients who are receiving opioids for their underlying persistent cancer pain where morphine is… | Mar 2006 | Recommended | no section in document |
Conditions are classified by a language model from the indication text of each submission, so an individual label here can be wrong. Consumer input is read from the document's own consumer comments section: 0 of 1 decisions since 2014 carried some. Silence means no comment reached the committee through that facility, not that nobody was affected. More on how this was built.